# Actinium 225 Labeled Anti-CEA Antibody (Ac225-DOTA-M5A) for the Treatment of CEA Producing Advanced or Metastatic Cancers

> **NCT05204147** · PHASE1 · SUSPENDED · sponsor: **City of Hope Medical Center** · enrollment: 20 (estimated)

## Conditions studied

- Advanced Cancer
- Metastatic Cancer

## Interventions

- **DRUG:** Actinium Ac 225-DOTA-anti-CEA Monoclonal Antibody M5A
- **PROCEDURE:** Biospecimen Collection

## Key facts

- **NCT ID:** NCT05204147
- **Lead sponsor:** City of Hope Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2022-06-02
- **Primary completion:** 2026-07-21
- **Final completion:** 2026-07-21
- **Target enrollment:** 20 (ESTIMATED)
- **Why stopped:** Drug Availability
- **Last updated:** 2026-04-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05204147

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05204147, "Actinium 225 Labeled Anti-CEA Antibody (Ac225-DOTA-M5A) for the Treatment of CEA Producing Advanced or Metastatic Cancers". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05204147. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*